Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Argenx Se (DE:1AEA)
MUNICH:1AEA
Argenx Se (1AEA) Stock Price & Analysis
2 Followers
1AEA Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€306.00 - €494.00
Previous Close€342
Volume0.00
Average Volume (3M)13.00
Market Cap
€20.75B
Enterprise Value€18.85B
Total Cash (Recent Filing)$2.05B
Total Debt (Recent Filing)$20.00M
Price to Earnings (P/E)N/A
Beta-0.13
Next Earnings
May 09, 2024EPS Estimate
-€0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding59,194,488
10 Day Avg. Volume0
30 Day Avg. Volume13
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)5.50
Price to Sales (P/S)16.41
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue88.43
Enterprise Value/Gross Profit17.01
Enterprise Value/Ebitda-41.34
Forecast
1Y Price Target
€442.30Price Target Upside29.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
Argenx Se News
PremiumCompany Announcements
Argenx’s VYVGART Shows Promising CIDP Treatment Results
PremiumCompany Announcements
Argenx Schedules Annual Shareholders’ Meeting 2024
PremiumCompany Announcements
Argenx Advances Promising Sjogren’s TreatmentBulls Say, Bears Say
Bulls Say
Drug Efficacy And SafetyVyvgart in gMG and CIDP after the AAN conference has shown a great degree of satisfaction with efficacy and safety, surpassing expectations from the ADAPT trial.
Regulatory MilestoneAdditional data strengthens confidence about the approval of Vyvgart Hytrulo for CIDP, with a PDUFA date set for FDA decision.
Treatment AdoptionVyvgart’s benefits were seen across all patient subtypes, indicating a broad potential patient base.
Bears Say
Clinical Trial OutcomesARGX’s Phase 3 in PV missed primary & secondary endpoints, resulting in a significant stock pullback.
Drug Development DecisionsManagement has discontinued further development in PV and is delaying decisions on other studies, indicating a reassessment of the drug's trajectory.
Market Access And PricingDue to exceeding the sales threshold, Vyvgart's price negotiations in Germany may lead to a lower price and pressure on sales in the short term.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
0.00% Mutual Funds
0.03% Other Institutional Investors
99.97% Public Companies and
Individual Investors
1AEA FAQ
What was Argenx Se’s price range in the past 12 months?
Argenx Se lowest stock price was €306.00 and its highest was €494.00 in the past 12 months.
What is Argenx Se’s market cap?
Currently, no data Available
When is Argenx Se’s upcoming earnings report date?
Argenx Se’s upcoming earnings report date is May 09, 2024 which is in 13 days.
How were Argenx Se’s earnings last quarter?
Argenx Se released its earnings results on Feb 29, 2024. The company reported -€1.575 earnings per share for the quarter, missing the consensus estimate of -€1.238 by -€0.337.
Is Argenx Se overvalued?
According to Wall Street analysts Argenx Se’s price is currently Undervalued.
Does Argenx Se pay dividends?
Argenx Se does not currently pay dividends.
What is Argenx Se’s EPS estimate?
Argenx Se’s EPS estimate is -€0.71.
How many shares outstanding does Argenx Se have?
Currently, no data Available
What happened to Argenx Se’s price movement after its last earnings report?
Argenx Se reported an EPS of -€1.575 in its last earnings report, missing expectations of -€1.238. Following the earnings report the stock price went down -3.723%.
Which hedge fund is a major shareholder of Argenx Se?
Among the largest hedge funds holding Argenx Se’s share is Baker Bros Advisors LP. It holds Argenx Se’s shares valued at 58M.
---
Argenx Se Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€442.30 (29.33% Upside)
€442.30 (29.33% Upside)
Blogger Sentiment
Bullish
DE:1AEA Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.67%
12-Months-Change
Fundamentals
Return on Equity
-8.55%
Trailing 12-Months
Asset Growth
44.93%
Trailing 12-Months
Company Description
Argenx Se
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.
---
1AEA Company Deck
---
1AEA Earnings Call
Q4 2024
0:00 / 0:00
---
1AEA Stock 12 Months Forecast
Average Price Target
€442.30
▲(29.33% Upside)
Technical Analysis
Best Analysts Covering 1AEA
1 Year
1 Year Success Rate
13/16 ratings generated profit
1 Year Average Return
+15.79%
reiterated a buy rating 12 months ago
Copying Danielle Brill's trades and holding each position for 1 Year would result in 81.25% of your transactions generating a profit, with an average return of +15.79% per trade.
---